Harmony Biosciences Reports Strong First Quarter Financial Results and Acceleration of Its Growth Strategy; Advances Pitolisant Franchise to Extend Revenue Potential Beyond 2040; Strenghtens Sleep/Wak

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/24/2026

1. SPCX
2. SPY
3. META
4. ABBV
5. FDX
6. IBM
7. NKE
8. MU
9. PFE
10. AWK

Go back to Harmony Biosciences Reports Strong First Quarter Financial Results and Acceleration of Its Growth Strategy; Advances Pitolisant Franchise to Extend Revenue Potential Beyond 2040; Strenghtens Sleep/Wak

Harmony Biosciences Holdings Inc. (HRMY) PT Raised to $37 at Raymond James

April 30, 2024 12:17 PM EDT

Raymond James analyst Danielle Brill raised the price target on Harmony Biosciences Holdings Inc. (NASDAQ: HRMY) to $37.00 (from $34.00) while maintaining a Outperform rating.

The analyst comments "Wakix 1Q sales of $154.6M (-8.2% q/q) slightly beat our $152.9M estimate (vs consensus $154.7M), and FY24 revenue guidance of... More

Harmony Biosciences (HRMY) Tops Q1 EPS by 25c

April 30, 2024 7:14 AM EDT

Harmony Biosciences (NASDAQ: HRMY) reported Q1 EPS of $0.88, $0.25 better than the analyst estimate of $0.63. Revenue for the quarter came in at $154.6 million versus the consensus estimate of $155.37 million.

Reiterates 2024 Net Product Revenue Guidance

Expect full year 2024 net product revenue of $700 million to $720 million

For... More